SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD

4.460

+0.020 (0.45%)

At close: Apr 18, 2024, 4:00 PM

4.410

-0.050 (-1.12%)

After-hours: Apr 18, 2024, 4:00 PM EDT

SAB Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-42.19	-18.74	-17.14	20.12	-8.99
Depreciation & Amortization	3.75	3.29	1.65	0.55	0.32
Share-Based Compensation	2.42	2.67	2.31	1.3	0.37
Other Operating Activities	10.91	-10.68	15.16	-11.96	-0.92
Operating Cash Flow	-25.12	-23.46	1.99	10	-9.21
Operating Cash Flow Growth	-	-	-80.14%	-	-
Capital Expenditures	-0.15	-2.09	-10.94	-12.72	-0.61
Investing Cash Flow	-0.15	-2.09	-10.94	-12.72	-0.61
Share Issuance / Repurchase	0.01	2.24	34.35	9.9	0
Debt Issued / Paid	-0.39	-1.19	1.54	-0.92	-0.62
Other Financing Activities	67.15	-	-	-	4.3
Financing Cash Flow	66.77	1.05	35.89	8.98	3.68
Exchange Rate Effect	0.02	0	0	0	0
Net Cash Flow	41.52	-24.5	26.93	6.26	-6.14
Free Cash Flow	-25.27	-25.55	-8.96	-2.72	-9.82
Free Cash Flow Margin	-1128.73%	-106.88%	-14.71%	-4.92%	-285.41%
Free Cash Flow Per Share	-4.58	-5.87	-3.28	-1.07	-2.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).